Tradestie Institutional Equity Comparison Engine
GRML vs IBO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IBO Overall Edge
IBO Captures Institutional Edge (3โ0 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Impact BioMedical, Inc. (IBO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, GRML trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus IBO at N/M Forward P/E and -12621.0% operating margin (+16.7% YoY). In options structure, GRML sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
IBO
GRML N/M vs IBO N/M Fwd P/E
Growth & Margin Winner
IBO
Op Margin N/A vs -12621.0% ยท YoY N/A vs +16.7%
Momentum & Technical Winner
IBO
1Y +650.0% vs +872.5% ยท 52W Pos 19% vs 68%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
GRML
US Equity
GRML
Institutional Equity
$3.51
-2.77% 1D
Market Cap
N/A
1M Return
-41.5%
1Y Return
+650.0%
Forward P/E
N/M
Unified AI Score
56.8 / 100
HOLD
Tech 60.0
Fund 57.0
Flow 50.0
Mom 60.0
IBO
NYSE American
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.96
-3.5% 1D
Market Cap
$41.2M
1M Return
+85.07%
1Y Return
+872.55%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 15.0
Fund 32.0
Flow 50.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
GRML +650.0%
IBO +872.55%
Spread: +135.56 pp (IBO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
GRML TTM Op. Margin: N/A
IBO TTM Op. Margin: -12621.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRML vs IBO. Trailing 12-month operating profitability (GRML N/A vs IBO -12621.0%) and valuation multiples (GRML N/M vs IBO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | GRML | IBO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $41.2M | Larger Scale | IBO |
| Trailing P/E Ratio Valuation | N/M | 0.4x | Lower Multiple | IBO |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +16.7% | Higher Growth | IBO |
| Operating Margin (TTM) Profitability | N/A | -12621.0% | Higher Margin | IBO |
| Net Profit Margin Profitability | N/A | 4247.4% | Higher Margin | IBO |
| Return on Equity (ROE) Capital Efficiency | N/A | 71.2% | Higher ROE | IBO |
| 52-Week Range Position Momentum | 19% ($0โ$18) | 68% ($0โ$7) | Stronger Trend | IBO |
| Beta / 30D Volatility Risk Regime | -5.32ฮฒ ยท 95% Vol | -6.75ฮฒ ยท 120% Vol | Lower Realized Risk | GRML |
| Unified Institutional Score Composite Signal | 56.8 / 100 (HOLD) | 36.8 / 100 (SELL) | Higher Composite | GRML |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full GRML vs IBO Buy Guide
GRML
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
IBO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither GRML nor IBO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.